UK doctors to seek permission to create baby with DNA from three people
By Ian Sample,
The Guardian
| 11. 30. 2016
Specialists poised to offer mitochondrial replacement therapy if government’s fertility regulator approves the treatment
Doctors will seek permission this month to create Britain’s first baby from the DNA of three people if the government’s fertility regulator approves the treatment for carefully chosen patients.
Specialists in Newcastle are ready to offer mitochondrial replacement therapy (MRT) to women who are in danger of passing on devastating and often fatal genetic disorders to their children. The conditions affect about one in 10,000 births.
A scientific review commissioned by the Human Fertilisation and Embryology Authority (HFEA) concluded on Wednesday that the therapy should be approved for “cautious clinical use” when children are at risk of inheriting specific genetic diseases.
The HFEA will now consider the findings and invite clinics to apply for licences if it endorses the recommendations at a meeting on 15 December. Last year, parliament changed the law to allow MRT, but scientists continued with further experiments to assess the treatment’s safety.
The Newcastle team has already selected patients who may be suitable for the therapy and plans to submit a licence...
Related Articles
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
By Jared Whitlock, Endpoints News | 10.09.2025
When Nirnay Murthy learned about a treatment for his toddler son’s rare condition, relief quickly gave way to disappointment.
A one-time gene therapy called Zolgensma from the Swiss drugmaker Novartis can halt spinal muscular atrophy, a deadly condition that causes...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...